Despite positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from pharmacy benefit managers. These insurers are typically building limitations to coverage, including steep read more price criteria and approval processes that limit user opportunity.